Atox Bio raises $23 million to fund flesh-eating bacteria treatment

Israel-based Atox Bio, a developer of therapeutics for severe infections, said on Thursday it has raised $23 million in an investment round led by SR One, the healthcare venture capital fund of GlaxoSmithKline. Lundbeck’s Lundbeckfond Ventures and OrbiMed Israel also invested. The funds will enable Atox Bio to initiate a late stage clinical study of AB103, for the treatment of necrotizing soft tissue infections (NSTI), commonly referred to as the “flesh eating bacteria” and other severe infections. AB103 completed a Phase 2 study in patients with NSTI.